JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB287680

Human PDGFB knockout MCF7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PDGFB KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Next Generation Sequencing - Human PDGFB knockout MCF7 cell line (AB287680)
  • NGS

Supplier Data

Next Generation Sequencing - Human PDGFB knockout MCF7 cell line (AB287680)

112 bp deletion after Arg99 of the WT protein.

Key facts

Cell type

MCF7

Species or organism

Human

Tissue

Breast

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Properties and storage information

Gene name
PDGFB
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • Slow to trypsinise.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 5-7x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

MEM + 10% FBS + 0.01 mg/ml bovine insulin

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PDGF-B also known as platelet-derived growth factor subunit B or PDGF-BB is a critical protein involved in various cellular processes. Composed of 241 amino acids PDGF-B exhibits a molecular mass of approximately 27 kDa. Scientists recognize this protein for its expression primarily in platelets but it also appears in a range of other tissues including smooth muscle cells and fibroblasts. The PDGF-B protein plays a substantial role in the regulation of growth and division inducing pathways important for cellular proliferation.
Biological function summary

PDGF-B influences cellular signaling processes and facilitates interactions that are a part of the PDGF receptor system. PDGF-B can form a homo-dimerization commonly known as the PDGF-BB dimer which is an active form. When PDGF-B binds to its receptor specifically the PDGF receptor β (PDGFR-β) it triggers pathways that control various cellular activities including growth and survival. The interaction of PDGF-B with the receptor is an important step that modulates several downstream signaling pathways.

Pathways

PDGF-B activates significant pathways such as the MAPK/ERK and PI3K/AKT pathways. These pathways play a major role in the regulation of cell proliferation and differentiation. Through these pathways PDGF-B exhibits interactions with proteins like Ras and Akt which are integral in transmitting signals within the cell. These cascades result in the promotion of processes such as angiogenesis and wound healing highlighting the importance of PDGF-B in cellular function.

Researchers have linked PDGF-B to pathologies such as cancer and atherosclerosis. For instance overexpression of PDGF-B can lead to abnormal vascular growth contributing to tumor development in cancers. It also plays a role in the progression of atherosclerosis by promoting the migration and proliferation of smooth muscle cells leading to plaque formation. In these contexts PDGF-B shows interaction with other proteins such as VEGF in tumor angiogenesis and LDL in atherosclerotic developments reinforcing its involvement in these conditions.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com